Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Kobe

Showing results (101-110 of 152) with videos related to

Pageof 16
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 3, 2025
PET imaging utilization and trends in Germany: a comprehensive surveyAdrien Holzgreve, Dirk Hellwig, Henryk Barthel, et al.
Clinical Nuclear Medicine|January 6, 2023
First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical CancerSimone Wegen, Katrin Sabine Roth, Jasmin Weindler, et al.
EJNMMI Physics|November 23, 2017
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task ForceCaroline Stokke, Pablo Minguez Gabiña, Pavel Solný, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Clinical Lung Cancer|December 12, 2018
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PETDiana S Y Abdulla, Matthias Scheffler, Vanessa Brandes, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Radiation Oncology (London, England)|April 4, 2024
Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancerSimone Wegen, Karina Claus, Philipp Linde, et al.
NPJ Precision Oncology|June 7, 2018
<i>ALK</i><sup>G1269A</sup> mutation as a potential mechanism of acquired resistance to crizotinib in an <i>ALK</i>-rearranged inflammatory myofibroblastic tumorSebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, et al.
JCO Precision Oncology|February 9, 2022
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLCSebastian Michels, Matthias Scheffler, Svenja Wagener, et al.
Pageof 16

Showing results (101-110 of 152) with videos related to

Sort By:
Pageof 16
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study GroupJan Kriz, Gabriele Reinartz, Markus Dietlein, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 3, 2025
PET imaging utilization and trends in Germany: a comprehensive surveyAdrien Holzgreve, Dirk Hellwig, Henryk Barthel, et al.
Clinical Nuclear Medicine|January 6, 2023
First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical CancerSimone Wegen, Katrin Sabine Roth, Jasmin Weindler, et al.
EJNMMI Physics|November 23, 2017
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task ForceCaroline Stokke, Pablo Minguez Gabiña, Pavel Solný, et al.
The Lancet. Oncology|November 15, 2017
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study GroupDennis A Eichenauer, Annette Plütschow, Stefanie Kreissl, et al.
Clinical Lung Cancer|December 12, 2018
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine PETDiana S Y Abdulla, Matthias Scheffler, Vanessa Brandes, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Radiation Oncology (London, England)|April 4, 2024
Impact of FAPI-46/dual-tracer PET/CT imaging on radiotherapeutic management in esophageal cancerSimone Wegen, Karina Claus, Philipp Linde, et al.
NPJ Precision Oncology|June 7, 2018
<i>ALK</i><sup>G1269A</sup> mutation as a potential mechanism of acquired resistance to crizotinib in an <i>ALK</i>-rearranged inflammatory myofibroblastic tumorSebastian Y F Michels, Andreas H Scheel, Thomas Wündisch, et al.
JCO Precision Oncology|February 9, 2022
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLCSebastian Michels, Matthias Scheffler, Svenja Wagener, et al.
Pageof 16